Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Investor Presentation (October 2026)
25 slides from Mayne Pharma's investor presentation, Oct 26, 2026
Slide 1: Mayne Pharma Group Limited Investor Presentation
rsonal use only Mayne Pharma Group Limited Investor Presentation Aaron Gray (CEO) Griffin Buchanan (CFO) 26 October 2026
Slide 2: Disclaimer
Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market rsonal use only disclosures. This material is not intended to be relied upon as advice to investors or
Slide 3: Snapshot
Snapshot Corporate Summary1,2 • Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more rsonal use only accessible medicines Share price (ASX:MYX) $2.45 GICS Industry Group Code (Pharmaceuticals) 3520201
Slide 4: Mayne Pharma in 2026
Mayne Pharma in 2026 Branded Product Sales Now Represent a Significant Proportion (%) of Mayne Pharma’s Net Sales, Driving Margin Expansion rsonal use only FY24 FY25 FY26 32% 68% 21% 79% 17% 83% 68% Branded │ 32% Generic 79% Branded │ 21% Generic 83% Branded │ 17% Generic 56% Gross Margin 61% Gross
Slide 5: FY26 Corporate Highlights
FY26 Corporate Highlights A year of resilience and focus against a backdrop of general operational distraction and disruption rsonal use only Realignment of Women’s Health Sales Force • Refreshed sales and marketing materials • Dedicated menopause and contraception field representation driving deepe
Slide 6: Global Headcount & Sales Force
Global Headcount & Sales Force Global footprint T O TA L H E A D C O U N T 1 470 Employees rsonal use only United States Current Women’s Health sales representation of ~90 persons 227 82% Employees FY26 sales mix Lexington, KY | Raleigh, NC Current DistributeRx sales representation of 22 persons May
Slide 7: FY26 Financial Highlights
FY26 Financial Highlights1 Margin expansion and resilient segment contribution through a year of disruption and reinvestment rsonal use only $383.7m 64.7% $34.2m Revenue Gross margin Underlying EBITDA2 down 6% FY25 Up 4.1% from 60.6% FY25 down 27% from $47.0m FY25 $107.1m $34.5m $80.0m Total direct
Slide 8: FY26 Snapshot – Segments
rsonal use only FY26 Snapshot – Segments FY26 Revenue Contribution FY26 Segment Contribution FY26 Total Direct Contribution (A$m, % of total) (A$m, % of total) A$4.6, 4% A$70.7, 18% A$44.5, 42% $107.1m A$138.7, 36% A$174.3, 46% A$57.9, 54% Women’s Health Dermatology/DistributeRx International 8
Slide 9: 1Q FY27 Review
rsonal use only 1Q FY27 Review
Slide 10: 1Q FY27 Financial Results
1Q FY27 Financial Results1 1Q FY27 reflects solid momentum from Women’s Health, offset by a decline in higher margin branded Dermatology sales rsonal use only $95.7m 63% $5.3m Revenue Gross margin Underlying EBITDA2 down 2% from 1Q FY26 down from 67% 1Q FY26 down 52% from 1Q FY26 $23.3m -$2.1m $67.3
Slide 11: 1Q FY27 Unaudited EBITDA & Cash Flow
1Q FY27 Unaudited EBITDA & Cash Flow1 Underlying EBITDA EBITDA ($m) Restructuring & Other Legal costs 0.9 rsonal use only 6.0 • Reported EBITDA of -$1.6 million: an improvement of 48% on the pcp 5.3 • Underlying EBITDA of $5.3 million: down 52% on the pcp • 1Q of each FY period most US patients have
Slide 12: 1Q FY27 Operating & Financial Highlights (Segments)
rsonal use only 1Q FY27 Operating & Financial Highlights (Segments) Women’s Health Dermatology/DistributeRx • Policy tailwinds with first US congressional hearing on menopause • gACCUTANE® closed 1Q at ~69% category share; result reflects held; Illinois mandates menopause treatment coverage generic
Slide 13: 1Q FY27 Operating & Financial Highlights (Segments)
1Q FY27 Operating & Financial Highlights (Segments) International Corporate rsonal use only • NEXTSTELLIS® demand cycles up 306% versus pcp, up 35% on 4Q • Cash and marketable securities of $67.3 million at 30 September FY261 2026 • BLISSEL® Australian licence signed; launch targeted in FY28 • Posit
Slide 14: Women's Health
rsonal use only Women’s Health
Slide 15: Women's Health
Women’s Health Global footprint An Exclusively Licensed Portfolio for the US Market; manufacturing via third parties Last Patent Expiry1 Branded Products US Indication Deal Structure and Terms rsonal use only Licensor: TherapeuticsMD (TXMD) 2032 Menopause • December 2022 • Cash consideration to TXMD
Slide 16: The Rise of Menopause
The Rise of Menopause Global footprint Key Drivers FY26 Penetration of Category1: ~1% rsonal use only 90 84 Total Prescriptions (TRx, ‘000) 77 80 67 • Regulatory de-risking of the category: FDA announced black boxed-warning 70 61 removal for certain hormone replacement therapies (HRTs) in Nov 2025 6
Slide 17: Contraception
Contraception Global footprint FY26 Penetration of Category1: ~3% Key Drivers Demand cycles (‘000) and Sequential Growth (%) Net Sales (US$m) & Growth (%) rsonal use only 28.0 63% 4% 9% 10.6% 11.7% 22.4 23% 23.4 216 21.8 2.9% -0.6% 194 • 23.0 20.1 Affordable Care Act benefits: payers showing more wi
Slide 18: Dermatology and DistributeRx
rsonal use only Dermatology and DistributeRx
Slide 19: Dermatology Products
Dermatology Products Global footprint A portfolio of branded and generics Branded Portfolio rsonal use only Last Patent Expiry Dermatology 2030 6 Branded Products 2034 20351 25 Generics, Authorised Generics Products 2039 31 Total Mayne Pharma Dermatology Products 2041 2041 19 1. RHOFADE® generic lau
Slide 20: Mayne Pharma Disintermediation
Mayne Pharma Disintermediation Disintermediation: rsonal use only Involves removing the intermediaries (wholesalers or others) between the manufacturer (Mayne Pharma) and the patient DistributeRx is Mayne Pharma's direct-to-patient distribution platform with Adelaide Apothecary serving as Mayne 60%
Slide 21: Prescription Access Made Simple
PRESCRIPTION ACCESS MADE SIMPLE rsonal use only DistributeRx partners with manufacturers, providers, and pharmacies to improve patient access and offer predictable prices • ePharmacy size ~US$252 billion by 2030 (CAGR 17%)1 driven by rising consumer adoption of digital pharmacy and home delivery • D
Slide 22: DistributeRx product portfolio
Global footprint 100% Mayne Pharma owned subsidiary with a portfolio of branded and generics, both Mayne Pharma owned and Via Third Parties rsonal use only 31 Mayne Pharma Dermatology Products1 + 211 Other Non-Mayne Products sold via DistributeRx Channel1 239 Total Products 12 Additional Pipeline Pr
Slide 23: Legal Overhang Materially Reduced
Legal Overhang Materially Reduced Global footprint ® Legacy legal matter closed, IMVEXXY IP secured, Cosette appeal dismissed Legal Matters - Summary Positive Impacts rsonal use only US State Attorneys General – generics SETTLED 28 Sep Lower costs Ongoing legal spend 2026 Resolved for US$0.65m with
Slide 24: FY27 focus and outlook
rsonal use only FY27 focus and outlook • Women’s Health: accelerate portfolio growth through a focused salesforce, refreshed marketing and improved prescriber access, underpinned by the macro tailwind from the removal of the HRT Black Box warning of the menopause category, in particular for BIJUVA®
Slide 25: Q&A
Q&A rsonal use only For further information contact: Dr Tom Duthy Investor Relations +61 402 493 727 ir@maynepharma.com Click here to view this Presentation on Investor Hub This presentation has been approved for release by the Board of Directors of Mayne Pharma You deserve tomorrow. 25
Mayne Pharma Group — Investor Presentation (October 2026) on 6ix